The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

Biopharmaceuticals stock Gilead Sciences (NASDAQ: GILD) jumped 2.5% through 12:30 p.m. ET Friday after Needham & Co. upgraded ...

Acting Columbia president speaks out after $220 million settlement with Trump admin.

In May 2024 Gilead shared stages with international gospel artistes Todd Galberth and Phil Thompson at the Mindset Conference ...

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...

Gilead (GILD) wins the backing of an EU panel for lenacapavir, its twice-yearly injectable for prevention of HIV in ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

Gilead Sciences (GILD) stock gains as Needham upgrades the company to Buy from Hold citing its new HIV prevention injectable, ...

CHENNAI: Gilead Sciences has achieved another milestone in its efforts to bring in a preventive drug to curb the still ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products ...

Gilead on Friday said the recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use covers lenacapavir for use as pre-exposure prophylaxis, or PrEP, to reduce ...